GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alexion Pharmaceuticals Inc (NAS:ALXN) » Definitions » Shiller PE Ratio

Alexion Pharmaceuticals (Alexion Pharmaceuticals) Shiller PE Ratio : 62.07 (As of Apr. 25, 2024)


View and export this data going back to 1996. Start your Free Trial

What is Alexion Pharmaceuticals Shiller PE Ratio?

As of today (2024-04-25), Alexion Pharmaceuticals's current share price is $182.50. Alexion Pharmaceuticals's E10 for the quarter that ended in Mar. 2021 was $2.94. Alexion Pharmaceuticals's Shiller PE Ratio for today is 62.07.

The historical rank and industry rank for Alexion Pharmaceuticals's Shiller PE Ratio or its related term are showing as below:

ALXN' s Shiller PE Ratio Range Over the Past 10 Years
Min: 30.46   Med: 59.73   Max: 98.74
Current: 61.61

During the past years, Alexion Pharmaceuticals's highest Shiller PE Ratio was 98.74. The lowest was 30.46. And the median was 59.73.

ALXN's Shiller PE Ratio is not ranked
in the Biotechnology industry.
Industry Median: 33.335 vs ALXN: 61.61

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Alexion Pharmaceuticals's adjusted earnings per share data for the three months ended in Mar. 2021 was $2.860. Add all the adjusted EPS for the past 10 years together and divide 10 will get our E10, which is $2.94 for the trailing ten years ended in Mar. 2021.

Shiller PE for Stocks: The True Measure of Stock Valuation


Alexion Pharmaceuticals Shiller PE Ratio Historical Data

The historical data trend for Alexion Pharmaceuticals's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alexion Pharmaceuticals Shiller PE Ratio Chart

Alexion Pharmaceuticals Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 67.12 46.25 59.58

Alexion Pharmaceuticals Quarterly Data
Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 33.81 52.50 47.30 59.58 52.27

Competitive Comparison of Alexion Pharmaceuticals's Shiller PE Ratio

For the Biotechnology subindustry, Alexion Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alexion Pharmaceuticals's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alexion Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Alexion Pharmaceuticals's Shiller PE Ratio falls into.



Alexion Pharmaceuticals Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Alexion Pharmaceuticals's Shiller PE Ratio for today is calculated as

Shiller PE Ratio=Share Price/ E10
=182.50/2.94
=62.07

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alexion Pharmaceuticals's E10 for the quarter that ended in Mar. 2021 is calculated as:

For example, Alexion Pharmaceuticals's adjusted earnings per share data for the three months ended in Mar. 2021 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2021 (Change)*Current CPI (Mar. 2021)
=2.86/111.7544*111.7544
=2.860

Current CPI (Mar. 2021) = 111.7544.

Alexion Pharmaceuticals Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201106 0.180 95.235 0.211
201109 0.340 95.727 0.397
201112 0.250 95.213 0.293
201203 0.230 96.783 0.266
201206 0.180 96.819 0.208
201209 0.460 97.633 0.527
201212 0.400 96.871 0.461
201303 0.410 98.209 0.467
201306 0.480 98.518 0.544
201309 0.470 98.790 0.532
201312 -0.100 98.326 -0.114
201403 0.790 99.695 0.886
201406 0.830 100.560 0.922
201409 0.880 100.428 0.979
201412 0.760 99.070 0.857
201503 0.450 99.621 0.505
201506 0.830 100.684 0.921
201509 -0.810 100.392 -0.902
201512 0.290 99.792 0.325
201603 0.410 100.470 0.456
201606 0.530 101.688 0.582
201609 0.420 101.861 0.461
201612 0.410 101.863 0.450
201703 0.750 102.862 0.815
201706 0.730 103.349 0.789
201709 0.350 104.136 0.376
201712 0.130 104.011 0.140
201803 1.110 105.290 1.178
201806 -2.050 106.317 -2.155
201809 1.470 106.507 1.542
201812 -0.200 105.998 -0.211
201903 2.610 107.251 2.720
201906 2.040 108.070 2.110
201909 2.080 108.329 2.146
201912 4.000 108.420 4.123
202003 2.500 108.902 2.565
202006 -4.840 108.767 -4.973
202009 2.620 109.815 2.666
202012 2.420 109.897 2.461
202103 2.860 111.754 2.860

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Alexion Pharmaceuticals  (NAS:ALXN) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Alexion Pharmaceuticals Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Alexion Pharmaceuticals's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Alexion Pharmaceuticals (Alexion Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
121 Seaport Boulevard, Boston, MA, USA, 02210
Alexion Pharmaceuticals specializes in developing and marketing drugs for rare, life-threatening medical conditions. Its blockbuster product, Soliris, is approved for paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). Next-generation Ultomiris is approved in PNH and aHUS. Strensiq and Kanuma target ultrarare metabolic diseases. Alexion's pipeline targets rare diseases with high unmet need in hematology, nephrology, metabolic diseases, neurology, cardiology, and other areas.
Executives
Daniel Bazarko officer: SVP, Controller, CAO C/O ALEXION PHARMACEUTICALS, INC. 121 SEAPORT BOULEVARD BOSTON MA 02210
Tanisha Carino officer: EVP & CCAO C/O ALEXION PHARMACEUTICALS, INC., 121 SEAPORT BOULEVARD, BOSTON MA 02210
Anne-marie Law officer: EVP, Chief Experience Officer C/O BAXALTA INCORPORATED, 1200 LAKESIDE DRIVE, BANNOCKBURN IL 60015
Brian Goff officer: EVP & Chief Commercial Officer C/O ALEXION PHARMACEUTICALS, INC, 100 COLLEGE STREET, NEW HAVEN CT 06510
John J Orloff officer: EVP, Research & Development C/O BAXALTA INCORPORATED 1200 LAKESIDE DRIVE BANNOCKBURN IL 60015
Indrani Lall Franchini officer: EVP, Chief Compliance Officer C/O ALEXION PHARMACEUTICALS, INC, 100 COLLEGE STREET, NEW HAVEN CT 06510
John T Mollen director 176 SOUTH STREET HOPKINTON MA 01748
David R Brennan director C/O INSMED INCORPORATED, 10 FINDERNE AVENUE, BRIDGEWATER NJ 08807
Baker Bros. Advisors (gp) Llc director 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
L.p. 667, director 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Andreas Rummelt director C/O ALEXION PHARMACEUTICALS, INC. 352 KNOTTER DRIVE CHESHIRE CT 06410
Francois Nader director 550 HILLS DRIVE, BEDMINSTER NJ 07921
Baker Brothers Life Sciences Lp director 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Deborah Dunsire director C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949
Judith A Reinsdorf director C. R. BARD, INC., 730 CENTRAL AVENUE, MURRAY HILL NJ 07974

Alexion Pharmaceuticals (Alexion Pharmaceuticals) Headlines

From GuruFocus